Improved Radiological Localization of Spinal Cord Lesions in Multiple Sclerosis (P03.060)

Abstract

Objective: To classify spinal cord lesions in multiple sclerosis (MS) based on white matter (WM) columns, and grey matter (GM) and WM involvement using magnetic resonance imaging (MRI). Background The localization of spinal cord lesions has not been well documented on MRI, although morphology and distribution of plaques have been characterized in post-mortem studies. Design/Methods: MRI was performed on the cervical cord in 16 MS patients (10 female, mean age 44.8) (8 relapsing remitting (RR) MS, 7 secondary progressive (SP) MS, 1 clinically isolated syndrome (CIS)). Axial phase sensitive inversion recovery (PSIR) and gradient-echo sequences were acquired. Two readers reviewed both images simultaneously and reached a consensus about classification of lesions by location: anterior (AC), lateral (LC) or posterior columns (PC). A sub-classification of lesions in mixed WM/GM and those involving WM only was also performed. Lesions were outlined manually on PSIR images and compared with mean cord area. Results: 51 lesions were identified, 24 in RRMS, 22 in SPMS, 5 in CIS. Three lesions were seen in AC (5.8%), 18 in PC (35.3%) and 30 in LC (58.9%). 33% of lesions involved WM alone and 67% involved both GM and WM; no pure GM lesions were identified. Mean lesion area in AC was 4.3mm2, LC 8.5mm2, PC 11.3mm2, with lesions in each column covering 6.1%, 12% and 16.1% of mean cord area respectively, mean lesion length in AC 18.3mm, LC 17.6mm and PC 24.8mm. Conclusions: Most lesions seen involved GM and WM, and were in the PC and LC, in agreement with post-mortem studies. However, no pure GM lesions were seen, suggesting technical limitations or a difference in patient characteristics from post-mortem studies. MRI may permit classification of spinal cord lesion location, area and length, which maybe correlated in future with disability to provide new insights into their functional effects. Supported by: MS Society. Disclosure: Dr. Kearney has nothing to disclose. Dr. Miszkiel has received research support from Biogen Idec and GlaxoSmithKline, Inc. Dr. Yiannakas has nothing to disclose. Dr. Ciccarelli has nothing to disclose. Dr. Miller has received personal compensation for activities with UCL Institute of Neurology, Biogen Idec, GlaxoSmithKline, and Bayer Schering Pharma. Dr. Miller has received personal compensation in an editorial capacity for Journal of Neurology. Dr. Miller has received research support from GlaxoSmithKline, Biogen Idec, and Novartis.